Cell line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations
J. Gomez Tejeda Zanudo, P. Mao, C. Alcon, K. J. Kowalski, G. N. Johnson, G. Xu, J. Baselga, M. Scaltriti, A. Letai, J. Montero, R. Albert, N. Wagle
bioRxiv · Aug 25, 2020Cancer Biology